These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 38557857

  • 1. Efficacy of Newer Nucleos(t)ide Analogs After Hepatitis B Immunoglobulin Discontinuation Against Hepatitis B and D Recurrence in Liver Transplant Recipients.
    Cholongitas E, Oikonomou T, Bafa K, Sinakos E, Papatheodoridis GV, Goulis I.
    Transplantation; 2024 Sep 01; 108(9):e239-e244. PubMed ID: 38557857
    [Abstract] [Full Text] [Related]

  • 2. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
    Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Giakoustidis D, Giouleme O, Papanikolaou V, Akriviadis E, Vasiliadis T.
    Transpl Infect Dis; 2016 Oct 01; 18(5):667-673. PubMed ID: 27421122
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E.
    Transpl Infect Dis; 2012 Oct 01; 14(5):479-87. PubMed ID: 22624695
    [Abstract] [Full Text] [Related]

  • 4. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS, Saraf N, Saigal S, Mohanka R, Rastogi A, Goja S, Menon PB, Soin AS.
    Transpl Infect Dis; 2015 Jun 01; 17(3):329-33. PubMed ID: 25682715
    [Abstract] [Full Text] [Related]

  • 5. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T, Hartmann J, Weimann A, Maier M, Bartels M, Jonas S, Mössner J, Berg T, Tillmann HL, Wiegand J.
    Transpl Infect Dis; 2011 Jun 01; 13(3):299-302. PubMed ID: 21159112
    [Abstract] [Full Text] [Related]

  • 6. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I, Loinaz C, Hernández O, Abradelo M, Manrique A, Calvo J, Manzano M, García A, Cambra F, Castellano G, Jiménez C.
    Transpl Infect Dis; 2015 Oct 01; 17(5):695-701. PubMed ID: 26257166
    [Abstract] [Full Text] [Related]

  • 7. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review.
    Cholongitas E, Papatheodoridis GV.
    Am J Transplant; 2013 Feb 01; 13(2):353-62. PubMed ID: 23137006
    [Abstract] [Full Text] [Related]

  • 8. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.
    Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS.
    Liver Transpl; 2007 Mar 01; 13(3):374-81. PubMed ID: 17318855
    [Abstract] [Full Text] [Related]

  • 9. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
    Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL.
    Transplantation; 2014 Apr 27; 97 Suppl 8():S53-9. PubMed ID: 24849836
    [Abstract] [Full Text] [Related]

  • 10. Limited hepatitis B immunoglobulin with potent nucleos(t)ide analogue is a cost-effective prophylaxis against hepatitis B virus after liver transplantation.
    Singer GA, Zielsdorf S, Fleetwood VA, Alvey N, Cohen E, Eswaran S, Shah N, Chan EY, Hertl M, Fayek SA.
    Transplant Proc; 2015 Mar 27; 47(2):478-84. PubMed ID: 25769595
    [Abstract] [Full Text] [Related]

  • 11. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
    Khemichian S, Hsieh MJ, Zhang SR, Limurti J, Kim J, Fong TL.
    Dig Dis Sci; 2015 Sep 27; 60(9):2807-12. PubMed ID: 25939541
    [Abstract] [Full Text] [Related]

  • 12. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
    Shen S, Jiang L, Xiao GQ, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Xu MQ, Wei YG.
    World J Gastroenterol; 2015 Jan 14; 21(2):584-92. PubMed ID: 25593480
    [Abstract] [Full Text] [Related]

  • 13. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence.
    Idilman R, Akyildiz M, Keskin O, Gungor G, Yilmaz TU, Kalkan C, Dayangac M, Cinar K, Balci D, Hazinedaroglu S, Tokat Y.
    Clin Transplant; 2016 Oct 14; 30(10):1216-1221. PubMed ID: 27409074
    [Abstract] [Full Text] [Related]

  • 14. Successful clinical and virological outcomes of liver transplantation for HDV/HBV-related disease after long-term discontinuation of hepatitis B immunoglobulins.
    Lenci I, Tariciotti L, Angelico R, Milana M, Signorello A, Manzia TM, Toti L, Tisone G, Angelico M, Baiocchi L.
    Clin Transplant; 2023 Jun 14; 37(6):e14971. PubMed ID: 36928864
    [Abstract] [Full Text] [Related]

  • 15. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW.
    Liver Transpl; 2013 Mar 14; 19(3):268-74. PubMed ID: 23447403
    [Abstract] [Full Text] [Related]

  • 16. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
    Darweesh SK, Gad AA, Akroof K, ElLatif ZA.
    Eur J Gastroenterol Hepatol; 2019 May 14; 31(5):607-612. PubMed ID: 30724767
    [Abstract] [Full Text] [Related]

  • 17. Prevention of hepatitis B virus reinfection in liver transplant recipients.
    Roche B, Samuel D.
    Intervirology; 2014 May 14; 57(3-4):196-201. PubMed ID: 25034488
    [Abstract] [Full Text] [Related]

  • 18. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients.
    Manini MA, Bruce M, Whitehouse G, Mazzarelli C, Considine A, Agarwal K, Suddle A, Fagiuoli S, Heaton N, Heneghan M.
    Transplant Proc; 2021 May 14; 53(1):207-214. PubMed ID: 32605776
    [Abstract] [Full Text] [Related]

  • 19. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence.
    Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, Akriviadis E.
    Transpl Int; 2014 Oct 14; 27(10):1022-8. PubMed ID: 24909714
    [Abstract] [Full Text] [Related]

  • 20. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
    Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, Considine A, Lampertico P, Suddle A, Heaton N, Heneghan M, Agarwal K.
    Dig Liver Dis; 2018 Sep 14; 50(9):944-953. PubMed ID: 29735294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.